Squarepoint
CBIO

Squarepoint’s Crescent Biopharma CBIO Stock Holding History

Squarepoint’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$435K Buy
+24,166
New +$472K ﹤0.01% 3524
2024
Q2 		– Sell
-203
Closed -$60.9K – 4274
2024
Q1 		$60.9K Buy
+203
New +$60.6K ﹤0.01% 3861
2021
Q3 		– Sell
-162
Closed -$38K – 3097
2021
Q2 		$38K Buy
+162
New +$41.2K ﹤0.01% 3124
2021
Q1 		– Sell
-399
Closed -$150K – 3293
2020
Q4 		$150K Buy
399
+81
+25% +$28.4K ﹤0.01% 2620
2020
Q3 		$98K Sell
318
-178
-36% -$68K ﹤0.01% 2291
2020
Q2 		$187K Sell
496
-378
-43% -$107K ﹤0.01% 1838
2020
Q1 		$199K Buy
874
+136
+18% +$52K 0.01% 1479
2019
Q4 		$390K Buy
738
+250
+51% +$135K ﹤0.01% 1903
2019
Q3 		$210K Buy
+488
New +$314K ﹤0.01% 2056
2019
Q1 		– Sell
-841
Closed -$797K – 2253
2018
Q4 		$797K Buy
841
+607
+259% +$730K 0.01% 1013
2018
Q3 		$337K Buy
+234
New +$354K ﹤0.01% 1479
2017
Q4 		– Sell
-375
Closed -$524K – 2178
2017
Q3 		$524K Buy
+375
New +$440K 0.01% 961

Other funds holding CBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Squarepoint's CBIO Position: Q2 2026 in Review

Squarepoint opened a new position in Crescent Biopharma (CBIO) in Q2 2026: 24,166 shares worth $435K. The stake represents ﹤0.01% of the portfolio and ranks #3524 among its holdings. This is a return to the name: Squarepoint previously reported a position in CBIO as recently as Q1 2024.

Squarepoint first reported a position in CBIO in Q3 2017 and has held it in 12 quarters since. The position peaked at $797K in Q4 2018. 82 funds tracked by Wall St. Rank hold CBIO as of Q2 2026.

  • Squarepoint held 24,166 shares of Crescent Biopharma worth $435K as of Q2 2026.
  • Crescent Biopharma was a new Squarepoint position in Q2 2026.
  • Crescent Biopharma made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #3524 holding.
  • Squarepoint first reported a position in Crescent Biopharma in Q3 2017 and has held it in 12 quarters since.
  • Squarepoint's Crescent Biopharma position peaked at $797K in Q4 2018.
  • 82 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.